A case of progressive multifocal leukoencephalopathy (PML) with a classic clinical presentation but with unusual pathological and radiographic findings is reported. The pathology revealed evidence of prior hemorrhage, and imaging studies revealed focal cerebral atrophy as well as contrast enhancement on MR scans. The contrast enhancement was visible only by utilizing magnetization transfer pulses on T1-weighted scans. The case report indicates that image criteria for PML may need to be redefined in the future.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00004728-199503000-00025 | DOI Listing |
Cytopathology
January 2025
Department of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
This is the first case report describing the diagnostic value of dot-shaped inclusions associated with promyelocytic leukaemia nuclear bodies (PML-NBs) to define JC virus-infected glial cells in an intraoperative cytopathological diagnosis for progressive multifocal leukoencephalopathy (PML).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, MA, USA.
Background: Brain atrophy is a normal part of healthy aging, but it is aggravated by several neurodegenerative diseases. Previous studies have described a large heterogeneity in individual neurodegeneration patterns, but the underlying brain mechanisms are currently not fully understood. From a graph theory-based framework, the estimation of subject-specific focal or multifocal brain atrophy in healthy aging and in the preclinical stage of different neurodegenerative diseases, such as Alzheimer's disease (AD), will help to better understand individual atrophy networks and likely improve prediction of phenotypic heterogeneity in disease trajectories.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.
Background: The double-blind (DB) period of the DIAN-TU-001 phase 3 trial with gantenerumab provided evidence of significant but incomplete reduction of amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 in dominantly inherited Alzheimer's disease (DIAD).Subsequently, eligible participants transitioned to an open-label extension (OLE) period using higher doses of gantenerumab (1500mg SC-administered every two weeks [q2w]).
Method: 73 DIAD participants entered the OLE period.
Alzheimers Dement
December 2024
Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, MA, USA.
Background: Brain atrophy is a normal part of healthy aging, but it is aggravated by several neurodegenerative diseases. Previous studies have described a large heterogeneity in individual neurodegeneration patterns, but the underlying brain mechanisms are currently not fully understood. From a graph theory-based framework, the estimation of subject-specific focal or multifocal brain atrophy in healthy aging and in the preclinical stage of different neurodegenerative diseases, such as Alzheimer's disease (AD), will help to better understand individual atrophy networks and likely improve prediction of phenotypic heterogeneity in disease trajectories.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Vanderbilt University Medical Center, Nashville, TN, USA.
Background: We report the case of a 79-year-old woman with Alzheimer's disease who enrolled in a clinical study of lecanemab. After the third, biweekly infusion she suffered a seizure followed by aphasia and progressive encephalopathy. Magnetic resonance imaging revealed multifocal cerebral edema and an increased burden of cerebral microhemorrhages compared to pre-trial imaging.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!